{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:04:33Z","timestamp":1792217073040,"version":"4.4.0"},"reference-count":36,"publisher":"Massachusetts Medical Society","issue":"3","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"name":"CRISPR Therapeutics AG"},{"name":"Vertex Pharmaceuticals Incorporated"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,1,21]]},"DOI":"10.1056\/nejmoa2031054","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T12:30:17Z","timestamp":1607171417000},"page":"252-260","source":"Crossref","is-referenced-by-count":1926,"title":["CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia"],"prefix":"10.1056","volume":"384","author":[{"given":"Haydar","family":"Frangoul","sequence":"first","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Altshuler","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Domm","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda K.","family":"Eustace","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Foell","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu","family":"de la Fuente","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grupp","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony W.","family":"Ho","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Kattamis","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kernytsky","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lekstrom-Himes","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Li","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"de Montalembert","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujit","family":"Sheth","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Soni","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Wall","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Yen","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Center for Blood Cancer at the Children\u2019s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children\u2019s Research Hospital, Memphis (A.S.) \u2014 both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) \u2014 both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Ges\u00f9 Rome, Sapienza..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","article-title":"Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.","volume":"33","author":"Bauer DE","year":"2015","unstructured":"Bauer DE, Orkin SH. Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev 2015;33:62-70.26375765","journal-title":"Curr Opin Genet Dev"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease.","volume":"376","author":"Piel FB","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med 2017;376:1561-1573.28423290","journal-title":"N Engl J Med"},{"key":"e_1_3_5_4_2","first-page":"4","article-title":"Differences in the clinical and genotypic presentation of sickle cell disease around the world.","volume":"15","author":"Saraf SL","year":"2014","unstructured":"Saraf SL, Molokie RE, Nouraie M, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 2014;15:4-12.24361300","journal-title":"Paediatr Respir Rev"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia.","volume":"12","author":"Cao A","year":"2010","unstructured":"Cao A, Galanello R. Beta-thalassemia. Genet Med 2010;12:61-76.20098328","journal-title":"Genet Med"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMcibr1809628","article-title":"Hemoglobinopathies in the fetal position.","volume":"379","author":"Pasricha SR","year":"2018","unstructured":"Pasricha SR, Drakesmith H. Hemoglobinopathies in the fetal position. N Engl J Med 2018;379:1675-1677.30354961","journal-title":"N Engl J Med"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in \u03b2-thalassemia.","volume":"37","author":"Shah FT","year":"2019","unstructured":"Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in \u03b2-thalassemia. Blood Rev 2019;37:100588-100588.31324412","journal-title":"Blood Rev"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3324\/haematol.2015.136739","article-title":"The European Hematology Association Roadmap for European Hematology Research: a consensus document.","volume":"101","author":"Engert A","year":"2016","unstructured":"Engert A, Balduini C, Brand A, et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 2016;101:115-208.26819058","journal-title":"Haematologica"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.","volume":"74","author":"Platt OS","year":"1984","unstructured":"Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-656.6205021","journal-title":"J Clin Invest"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia.","volume":"382","author":"Cappellini MD","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med 2020;382:1219-1231.32212518","journal-title":"N Engl J Med"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga KI","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;376:429-439.27959701","journal-title":"N Engl J Med"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010.","volume":"51","author":"Baronciani D","year":"2016","unstructured":"Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016;51:536-541.26752139","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.","volume":"6","author":"Eapen M","year":"2019","unstructured":"Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol 2019;6(11):e585-e596.31495699","journal-title":"Lancet Haematol"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.","volume":"129","author":"Gluckman E","year":"2017","unstructured":"Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 2017;129:1548-1556.27965196","journal-title":"Blood"},{"key":"e_1_3_5_15_2","unstructured":"European Medicines Agency. Zynteglo: summary of product characteristics (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zynteglo-epar-product-information_en.pdf)."},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia.","volume":"378","author":"Thompson AA","year":"2018","unstructured":"Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med 2018;378:1479-1493.29669226","journal-title":"N Engl J Med"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease.","volume":"376","author":"Ribeil JA","year":"2017","unstructured":"Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017;376:848-855.28249145","journal-title":"N Engl J Med"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.","volume":"126","author":"Brendel C","year":"2016","unstructured":"Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest 2016;126:3868-3878.27599293","journal-title":"J Clin Invest"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.omtm.2020.03.015","article-title":"Preclinical evaluation of a novel lentiviral vector driving lineage-specific BCL11A knockdown for sickle cell gene therapy.","volume":"17","author":"Brendel C","year":"2020","unstructured":"Brendel C, Negre O, Rothe M, et al. Preclinical evaluation of a novel lentiviral vector driving lineage-specific BCL11A knockdown for sickle cell gene therapy. Mol Ther Methods Clin Dev 2020;17:589-600.32300607","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029392"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood-2011-09-382408","article-title":"Fetal hemoglobin levels and morbidity in untransfused patients with \u03b2-thalassemia intermedia.","volume":"119","author":"Musallam KM","year":"2012","unstructured":"Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with \u03b2-thalassemia intermedia. Blood 2012;119:364-367.22096240","journal-title":"Blood"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease: life expectancy and risk factors for early death.","volume":"330","author":"Platt OS","year":"1994","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.7993409","journal-title":"N Engl J Med"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.V63.4.921.921","article-title":"Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?","volume":"63","author":"Powars DR","year":"1984","unstructured":"Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984;63:921-926.6200161","journal-title":"Blood"},{"issue":"1","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"a011643","DOI":"10.1101\/cshperspect.a011643","article-title":"The switch from fetal to adult hemoglobin.","volume":"3","author":"Sankaran VG","year":"2013","unstructured":"Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med 2013;3(1):a011643-a011643.23209159","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/blood-2016-01-678128","article-title":"Customizing the genome as therapy for the \u03b2-hemoglobinopathies.","volume":"127","author":"Canver MC","year":"2016","unstructured":"Canver MC, Orkin SH. Customizing the genome as therapy for the \u03b2-hemoglobinopathies. Blood 2016;127:2536-2545.27053533","journal-title":"Blood"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood.2020007645","article-title":"Fetal hemoglobin in sickle cell anemia.","volume":"136","author":"Steinberg MH","year":"2020","unstructured":"Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood 2020;136:2392-2400.32808012","journal-title":"Blood"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.","volume":"342","author":"Bauer DE","year":"2013","unstructured":"Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013;342:253-257.24115442","journal-title":"Science"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of \u03b2-thalassemia.","volume":"105","author":"Uda M","year":"2008","unstructured":"Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of \u03b2-thalassemia. Proc Natl Acad Sci U S A 2008;105:1620-1625.18245381","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nprot.2017.143","article-title":"CRISPR\/Cas9 genome editing in human hematopoietic stem cells.","volume":"13","author":"Bak RO","year":"2018","unstructured":"Bak RO, Dever DP, Porteus MH. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc 2018;13:358-376.29370156","journal-title":"Nat Protoc"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.","volume":"33","author":"Hendel A","year":"2015","unstructured":"Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 2015;33:985-989.26121415","journal-title":"Nat Biotechnol"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.","volume":"527","author":"Canver MC","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 2015;527:192-197.26375006","journal-title":"Nature"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells.","volume":"25","author":"Wu Y","year":"2019","unstructured":"Wu Y, Zeng J, Roscoe BP, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 2019;25:776-783.30911135","journal-title":"Nat Med"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment.","volume":"22","author":"Dalle JH","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant 2016;22:400-409.26431626","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V91.7.2588","article-title":"Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors.","volume":"91","author":"Bomberger C","year":"1998","unstructured":"Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998;91:2588-2600.9516161","journal-title":"Blood"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/15258160050196777","article-title":"Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation.","volume":"9","author":"Nachbaur D","year":"2000","unstructured":"Nachbaur D, Kropshofer G, Heitger A, et al. Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation. J Hematother Stem Cell Res 2000;9:727-736.11091497","journal-title":"J Hematother Stem Cell Res"},{"key":"e_1_3_5_36_2","unstructured":"Corbacioglu S Cappellini MD Chapin J et al. Initial safety and efficacy results with a single dose of autologous CRISPR-CAS9 modified CD34+ hematopoietic stem and progenitor cells in transfusion-dependent \u03b2-thalassemia and sickle cell disease. Presented at the virtual European Hematology Association Congress June 11\u201314 2020. abstract."},{"key":"e_1_3_5_37_2","unstructured":"Frangoul H Bobruff Y Cappellini MD et al. Safety and efficacy of CTX001 in patients with transfusion-dependent \u03b2-thalassemia or sickle cell disease: early results from the CLIMB THAL-111 and CLIMB SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells. Presented at the American Society of Hematology Annual Meeting December 5\u20138 2020. abstract."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2031054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:35:00Z","timestamp":1711485300000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2031054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,21]]}},"alternative-id":["10.1056\/NEJMoa2031054"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2031054","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}